New pharmacological avenues for the treatment ofl-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors
出版年份 2012 全文链接
标题
New pharmacological avenues for the treatment ofl-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 21, Issue 2, Pages 153-168
出版商
Informa Healthcare
发表日期
2012-01-11
DOI
10.1517/13543784.2012.651457
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint
- (2011) Dag Nyholm et al. ANNALS OF NEUROLOGY
- Therapies for dopaminergic-induced dyskinesias in parkinson disease
- (2011) Mildred D. Gottwald et al. ANNALS OF NEUROLOGY
- Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias
- (2011) Imtiaz Ahmed et al. BRAIN
- Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release
- (2011) O. Rascol EUROPEAN JOURNAL OF NEUROLOGY
- The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D2/A2A Receptor Interaction in the Striatum: Implications for Parkinson's Disease
- (2011) A. Tozzi et al. JOURNAL OF NEUROSCIENCE
- Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
- (2011) Robert A Hauser et al. LANCET NEUROLOGY
- Milestones in PD genetics
- (2011) Thomas Gasser et al. MOVEMENT DISORDERS
- AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials
- (2011) Daniela Berg et al. MOVEMENT DISORDERS
- The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys
- (2011) Laurent Grégoire et al. PARKINSONISM & RELATED DISORDERS
- International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors--An Update
- (2011) B. B. Fredholm et al. PHARMACOLOGICAL REVIEWS
- Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial
- (2011) Hideyuki Sawada et al. PLoS One
- Striatal Pre- and Postsynaptic Profile of Adenosine A2A Receptor Antagonists
- (2011) Marco Orru et al. PLoS One
- The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-dopa-induced dyskinesias
- (2011) C. Marin et al. SYNAPSE
- Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study
- (2010) Fabrizio Stocchi et al. ANNALS OF NEUROLOGY
- An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of Vipadenant (BIIB014) at Steady-State Levels in Healthy Male Volunteers
- (2010) David J. Brooks et al. CLINICAL NEUROPHARMACOLOGY
- Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders
- (2010) Robert A. Hodgson et al. EXPERIMENTAL NEUROLOGY
- Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson’s disease
- (2010) Christopher Kobylecki et al. JOURNAL OF NEUROCHEMISTRY
- Quantification of Indirect Pathway Inhibition by the Adenosine A2a Antagonist SYN115 in Parkinson Disease
- (2010) K. J. Black et al. JOURNAL OF NEUROSCIENCE
- Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease
- (2010) T. H. Johnston et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A2A, dopamine D2, cannabinoid CB1, and metabotropic glutamate mGlu5receptors
- (2010) Luigi F. Agnati et al. JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
- Long-term antidyskinetic efficacy of amantadine in Parkinson's disease
- (2010) Elisabeth Wolf et al. MOVEMENT DISORDERS
- Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study
- (2010) Karla Eggert et al. MOVEMENT DISORDERS
- Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study
- (2010) Yoshikuni Mizuno et al. MOVEMENT DISORDERS
- Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat
- (2010) Manon Lebel et al. NEUROBIOLOGY OF DISEASE
- Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias
- (2010) B. Ouattara et al. NEUROSCIENCE
- A long-term study of istradefylline in subjects with fluctuating Parkinson's disease
- (2010) Stewart Factor et al. PARKINSONISM & RELATED DISORDERS
- Distinct Changes in cAMP and Extracellular Signal-Regulated Protein Kinase Signalling in L-DOPA-Induced Dyskinesia
- (2010) Emanuela Santini et al. PLoS One
- Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice
- (2010) Y. Ding et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily
- (2009) Mikko Kuoppamäki et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Novel investigational adenosine A2Areceptor antagonists for Parkinson's disease
- (2009) Annalisa Pinna EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression
- (2009) R. A. Hodgson et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling
- (2009) D. Rylander et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Metabotropic glutamate receptor type 5 in levodopa-induced motor complications
- (2009) Bazoumana Ouattara et al. NEUROBIOLOGY OF AGING
- Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats
- (2009) N. Yamamoto et al. NEUROSCIENCE
- Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson's disease
- (2009) Angelo Antonini et al. PARKINSONISM & RELATED DISORDERS
- Adenosine, adenosine A2A antagonists, and Parkinson's disease
- (2009) P. Jenner et al. PARKINSONISM & RELATED DISORDERS
- Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial
- (2009) H.H. Fernandez et al. PARKINSONISM & RELATED DISORDERS
- Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys
- (2009) Marc Morissette et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)
- (2008) Peter A. LeWitt et al. ANNALS OF NEUROLOGY
- Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia
- (2008) Joohyung Lee et al. BRAIN
- An Update on Adenosine A2A-Dopamine D2 Receptor Interactions: Implications for the Function of G Protein-Coupled Receptors
- (2008) S. Ferre et al. CURRENT PHARMACEUTICAL DESIGN
- Non-motor symptoms in Parkinson’s disease
- (2008) W. Poewe EUROPEAN JOURNAL OF NEUROLOGY
- Antagonists of the Human A2AAdenosine Receptor. 4. Design, Synthesis, and Preclinical Evaluation of 7-Aryltriazolo[4,5-d]pyrimidines
- (2008) Roger J. Gillespie et al. JOURNAL OF MEDICINAL CHEMISTRY
- Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease
- (2008) Alim Louis Benabid et al. LANCET NEUROLOGY
- Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
- (2008) Robert A. Hauser et al. MOVEMENT DISORDERS
- Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism
- (2008) John G. Nutt et al. MOVEMENT DISORDERS
- A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
- (2008) M. Stacy et al. NEUROLOGY
- Positron emission tomography analysis of [11C]KW‐6002 binding to human and rat adenosine A2Areceptors in the brain
- (2008) D.J. Brooks et al. SYNAPSE
- mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys
- (2007) Pershia Samadi et al. NEUROBIOLOGY OF AGING
- Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease
- (2007) Giovanna Levandis et al. NEUROBIOLOGY OF DISEASE
- l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation
- (2007) Barbara Picconi et al. NEUROBIOLOGY OF DISEASE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search